Pharmaceutical CDMO Market, By Service Type (Drug Development Services, Analytical and Regulatory Support, Clinical Manufacturing, Commercial Manufacturing, and Packaging & Serialization Services), By Technology, By Therapeutic Modality, By End-Use, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4853
|
Published Date
March 2026
|
Pages
353
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Pharmaceutical CDMO Market size was valued at US$ 180,418.09 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.
A Pharmaceutical Contract Development and Manufacturing Organization (CDMO) is a specialized partner that assists pharmaceutical and biotechnology companies in the development, production, and commercialization of drugs. CDMOs provide end-to-end services, including drug formulation, process optimization, clinical and commercial-scale manufacturing, analytical testing, and packaging solutions. By collaborating with CDMOs, companies gain access to advanced technologies, regulatory expertise, and scalable production capabilities, which help accelerate time-to-market while reducing costs. Beyond operational support, CDMOs serve as strategic partners, particularly for complex therapeutics such as biologics, cell therapies, and gene therapies, driving innovation, ensuring quality compliance, and promoting sustainable growth. From a global governance perspective, regulatory authorities and organizations such as the U.S. FDA, the European Medicines Agency (EMA), and the World Health Organization emphasize robust domestic manufacturing standards and supply chain resilience, encouraging CDMO engagement to expand vaccine production capacity and support public health initiatives worldwide.
Pharmaceutical CDMO Market- Market Dynamics
Growing Demand for Advanced Biologic Therapies to Drive Sustainable Healthcare Solutions
The increasing demand for advanced biologic therapies is driving significant growth in pharmaceutical manufacturing and outsourcing. Biologics—including monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies—are playing an essential role in treating complex chronic conditions such as cancer, autoimmune disorders, and metabolic diseases. Pharmaceutical companies are expanding their biologics pipelines to address this demand, while regulators in key markets are facilitating faster development and patient access. For example, the U.S. Food and Drug Administration (FDA) has updated guidance to streamline the approval of biosimilars and novel biologic therapies, improving availability and helping manage treatment costs.
To meet rising global demand, leading manufacturers are investing heavily in production capacity and strategic facilities. South Korea’s Samsung Biologics, for instance, is expanding its U.S. footprint by acquiring a Maryland-based production site to support biologics output and long-term supply commitments. On the policy front, India has launched a major initiative with an allocation of 10,000 crore over five years to strengthen biopharmaceutical manufacturing, positioning the country as a global hub for biologics and biosimilars. These coordinated public and private efforts highlight how advanced biologic therapies are shaping sustainable healthcare strategies worldwide.
Pharmaceutical CDMO Market- Segmentation Analysis:
The Global Pharmaceutical CDMO Market is segmented on the basis of Service Type, Technology, Therapeutic Modality, End-Use, and Region.
The pharmaceutical CDMO market is segmented by service type into five key categories: Drug Development Services, Analytical and Regulatory Support, Clinical Manufacturing, Commercial Manufacturing, and Packaging & Serialization Services. Among these, Commercial Manufacturing plays a central role, providing the large-scale production capacity that sponsors require once drugs successfully complete clinical development. For example, Lonza’s core CDMO operations—heavily focused on commercial manufacturing of both small molecules and biologics—generated CHF6.5billion in revenue in 2025, highlighting the critical contribution of this segment to overall growth and profitability. Government initiatives further emphasize the importance of scalable production; the U.S. Food and Drug Administration’s PreCheck program, for instance, streamlines facility inspections and strengthens domestic manufacturing infrastructure, underscoring commercial manufacturing’s pivotal role in ensuring reliable drug supply and market access.
From a therapeutic modality perspective, the market is divided into Small Molecules, Biologic Molecules, Advanced Therapies, Vaccines, and Specialized Formulations. While small molecules continue to dominate due to established production processes and lower complexity, biologic molecules are emerging as a key driver of CDMO demand because they require advanced technologies, specialized facilities, and strict regulatory oversight. Biologics—including monoclonal antibodies, recombinant proteins, and cell-based therapies—cannot be easily produced at scale in-house, which creates a strong reliance on outsourced manufacturing. Leading players such as Lonza and Samsung Biologics are investing heavily in biologics production capacity to meet this demand. At the same time, regulatory programs like the FDA’s accelerated biologics approval initiatives further reinforce the strategic priority of biologics in global pharmaceutical manufacturing and outsourcing.
Pharmaceutical CDMO Market- Geographical Insights
North America is poised to remain a central hub in the Pharmaceutical CDMO market, driven by strong investments from both government initiatives and private industry to strengthen domestic drug manufacturing capabilities. The U.S. Food and Drug Administration (FDA) has introduced programs such as the PreCheck Pilot Program, designed to streamline regulatory approvals and accelerate the development of new pharmaceutical manufacturing facilities nationwide. These efforts aim to reduce reliance on imports, enhance supply chain resilience, and expand local production capacity, aligning with national priorities to ensure reliable access to essential medicines.
At the same time, leading pharmaceutical companies are actively increasing their manufacturing presence in North America. For instance, Novartis is constructing a new radioligand therapy production site in Texas as part of a multi-facility expansion, while AbbVie is investing hundreds of millions of dollars to expand active pharmaceutical ingredient (API) manufacturing in Illinois. These initiatives reflect strong industry confidence in regional capabilities and the effectiveness of government incentives for domestic production. Collectively, public policy support and strategic corporate investments are reinforcing North America’s role as a key center for advanced pharmaceutical manufacturing and CDMO operations.
South Korea Pharmaceutical CDMO Market- Country Insights
South Korea has emerged as a key player in the global Pharmaceutical CDMO market, driven by proactive government support and a rapidly advancing biopharmaceutical industry. The government has identified biopharmaceuticals—including vaccines, mRNA therapeutics, and protein-based treatments—as a strategic sector, prioritizing policies that enhance long-term growth, self-reliance, and global competitiveness. Regulatory authorities are also considering legislation to strengthen CDMO activities and support export-oriented manufacturing, reflecting a broader commitment to pharmaceutical innovation and resilient global supply chains.
On the corporate front, Samsung Biologics, headquartered in Songdo, Incheon, exemplifies South Korea’s expanding presence in the CDMO sector. The company maintains significant manufacturing partnerships with international clients and continues to expand its production capacity. In 2025, Samsung Biologics reported revenues exceeding 4.5trillion Korean won and secured multiple long-term manufacturing agreements, highlighting sustained demand for its biopharmaceutical services. Strategic investments in additional facilities and advanced biologics platforms further solidify South Korea’s position as an emerging hub for contract development and manufacturing services in the global pharmaceutical landscape.
Pharmaceutical CDMO Market- Competitive Landscape:
The Pharmaceutical CDMO market is highly competitive, featuring a mix of global industry leaders and specialized regional providers delivering comprehensive drug development and manufacturing solutions. Companies differentiate themselves through technical expertise, regulatory compliance, production capacity, quality assurance, and speed to market. Leading players strategically focus on expanding manufacturing infrastructure, investing in biologics and advanced therapy capabilities, and enhancing analytical and regulatory support services. Common strategies include mergers and acquisitions, long-term partnerships with pharmaceutical sponsors, launch of new services, and geographic expansion to strengthen market presence. Firms such as Lonza, Samsung Biologics, and Catalent exemplify these approaches, reinforcing their global leadership and extensive client networks.
Recent Developments:
- In January 2026, Zydus established Zylidac Bio LLC, enhancing its U.S. biologics CDMO footprint and aligning with regulatory trends that support secure domestic manufacturing, thereby improving service availability for global biopharmaceutical partners.
- In September 2025, Terumo Corporation acquired a drug product plant and quality control operations from WuXi Biologics in Leverkusen, Germany, expanding its production capacity and quality control capabilities to better serve both domestic and international pharmaceutical clients.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PHARMACEUTICAL CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Catalent
- Thermo Fisher Scientific
- Lonza Group
- Recipharm AB
- Samsung Biologics
- WuXi AppTec
- Cambrex Corporation
- WuXi Biologics
- Piramal Pharma Solutions
- Corden Pharma International
- Vetter Pharma
- Eurofins CDMO
- Others
GLOBAL PHARMACEUTICAL CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032
- Drug Development Services
- Analytical and Regulatory Support
- Clinical Manufacturing
- Commercial Manufacturing
- Packaging & Serialization Services
GLOBAL PHARMACEUTICAL CDMO MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- Chemical Synthesis & API Manufacturing
- Fermentation & Bioprocessing
- FillFinish & Aseptic Processing
- Continuous Manufacturing
- Advanced Analytical Technologies
GLOBAL PHARMACEUTICAL CDMO MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2019 - 2032
- Small Molecules
- Biologic Molecules
- Advanced Therapies (Cell, Gene, and Tissue)
- Vaccines
- Specialized Formulations (e.g., liposomal, nanoparticle)
GLOBAL PHARMACEUTICAL CDMO MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032
- Large Pharmaceutical Companies
- Mid-Size Biotech Firms
- Virtual Pharma
- Public Health Programs
- Non-Profit Research Consortia
GLOBAL PHARMACEUTICAL CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Pharmaceutical CDMO Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Pharmaceutical CDMO Market Snippet by Service Type
2.1.2. Pharmaceutical CDMO Market Snippet by Technology
2.1.3. Pharmaceutical CDMO Market Snippet by Therapeutic Modality
2.1.4. Pharmaceutical CDMO Market Snippet by End-Use
2.1.5. Pharmaceutical CDMO Market Snippet by Country
2.1.6. Pharmaceutical CDMO Market Snippet by Region
2.2. Competitive Insights
3. Pharmaceutical CDMO Key Market Trends
3.1. Pharmaceutical CDMO Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Pharmaceutical CDMO Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Pharmaceutical CDMO Market Opportunities
3.4. Pharmaceutical CDMO Market Future Trends
4. Pharmaceutical CDMO Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Pharmaceutical CDMO Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Pharmaceutical CDMO Market Landscape
6.1. Pharmaceutical CDMO Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Pharmaceutical CDMO Market – By Service Type
7.1. Overview
7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
7.1.2. Drug Development Services
7.1.3. Analytical and Regulatory Support
7.1.4. Clinical Manufacturing
7.1.5. Commercial Manufacturing
7.1.6. Packaging & Serialization Services
8. Pharmaceutical CDMO Market – By Technology
8.1. Overview
8.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
8.1.2. Chemical Synthesis & API Manufacturing
8.1.3. Fermentation & Bioprocessing
8.1.4. Fill Finish & Aseptic Processing
8.1.5. Continuous Manufacturing
8.1.6. Advanced Analytical Technologies
9. Pharmaceutical CDMO Market – By Therapeutic Modality
9.1. Overview
9.1.1. Segment Share Analysis, By Therapeutic Modality, 2024 & 2032 (%)
9.1.2. Small Molecules
9.1.3. Biologic Molecules
9.1.4. Advanced Therapies (Cell, Gene, and Tissue)
9.1.5. Vaccines
9.1.6. Specialized Formulations (e.g., liposomal, nanoparticle)
10. Pharmaceutical CDMO Market – By End-Use
10.1. Overview
10.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
10.1.2. Large Pharmaceutical Companies
10.1.3. Mid Size Biotech Firms
10.1.4. Virtual Pharma
10.1.5. Public Health Programs
10.1.6. Non Profit Research Consortia
11. Pharmaceutical CDMO Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Pharmaceutical CDMO Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Pharmaceutical CDMO Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Pharmaceutical CDMO Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Pharmaceutical CDMO Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Pharmaceutical CDMO Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Pharmaceutical CDMO Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Catalent
12.2.2. Thermo Fisher Scientific
12.2.3. Lonza Group
12.2.4. Recipharm AB
12.2.5. Samsung Biologics
12.2.6. WuXi AppTec
12.2.7. Cambrex Corporation
12.2.8. WuXi Biologics
12.2.9. Piramal Pharma Solutions
12.2.10. Corden Pharma International
12.2.11. Vetter Pharma
12.2.12. Eurofins CDMO
12.2.13. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PHARMACEUTICAL CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Catalent
- Thermo Fisher Scientific
- Lonza Group
- Recipharm AB
- Samsung Biologics
- WuXi AppTec
- Cambrex Corporation
- WuXi Biologics
- Piramal Pharma Solutions
- Corden Pharma International
- Vetter Pharma
- Eurofins CDMO
- Others
GLOBAL PHARMACEUTICAL CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032
- Drug Development Services
- Analytical and Regulatory Support
- Clinical Manufacturing
- Commercial Manufacturing
- Packaging & Serialization Services
GLOBAL PHARMACEUTICAL CDMO MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- Chemical Synthesis & API Manufacturing
- Fermentation & Bioprocessing
- FillFinish & Aseptic Processing
- Continuous Manufacturing
- Advanced Analytical Technologies
GLOBAL PHARMACEUTICAL CDMO MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2019 - 2032
- Small Molecules
- Biologic Molecules
- Advanced Therapies (Cell, Gene, and Tissue)
- Vaccines
- Specialized Formulations (e.g., liposomal, nanoparticle)
GLOBAL PHARMACEUTICAL CDMO MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032
- Large Pharmaceutical Companies
- Mid-Size Biotech Firms
- Virtual Pharma
- Public Health Programs
- Non-Profit Research Consortia
GLOBAL PHARMACEUTICAL CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
